TAKEDA PHARMACEUTICAL CO LTD(TAK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TAK Stock Analysis & AI Quality Score
AI stock analysis and institutional research for TAKEDA PHARMACEUTICAL CO LTD (TAK), a Healthcare sector company. TAK is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of TAK by reported 13-F value include Capital Research Global Investors, FMR, MORGAN STANLEY, based on the most recent SEC filings. TAK trades on the NYSE exchange and files with the SEC under CIK 1395064. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TAK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TAKEDA PHARMACEUTICAL CO LTD directly from SEC EDGAR.
AI Insight: TAK Financial Trends
Insufficient financial data to assess Takeda's operational or financial trends.
• No financial metrics available across all periods (Q1 2019–Q1 2025). Data required to evaluate revenue, profitability, cash generation, or leverage trends.
⚠ Complete absence of quarterly financials prevents assessment of margin trajectory, debt dynamics, or cash flow sustainability.
AI Insight: TAK Ratio Trends
Insufficient data: all ratio fields are empty across the entire period, preventing trend analysis.
• No operating margin, net profit margin, ROE, ROA, ROIC, or debt-to-equity figures available for any quarter Q1 2019–Q1 2025.
⚠ Data completeness issue must be resolved to assess profitability, returns, and leverage trends.
Get alerted when TAK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for TAKEDA PHARMACEUTICAL CO LTD including:
Top Institutional Holders of TAK
Capital Research Global Investors
$353.8M19,104,219 shFMR LLC
$131.8M7,117,486 shMORGAN STANLEY
$119.8M6,469,600 shADAGE CAPITAL PARTNERS GP, L.L.C.
$119.0M6,424,984 shGOLDMAN SACHS GROUP INC
$104.1M5,618,728 shPacer Advisors, Inc.
$91.2M2,359,239 shBRANDES INVESTMENT PARTNERS, LP
$82.1M4,430,642 shBlackRock, Inc.
$58.8M3,176,421 shARROWSTREET CAPITAL, LIMITED PARTNERSHIP
$57.7M3,116,311 shRENAISSANCE TECHNOLOGIES LLC
$55.4M2,989,100 sh
| Fund | Value | Shares |
|---|---|---|
| Capital Research Global Investors | $353.8M | 19,104,219 |
| FMR LLC | $131.8M | 7,117,486 |
| MORGAN STANLEY | $119.8M | 6,469,600 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $119.0M | 6,424,984 |
| GOLDMAN SACHS GROUP INC | $104.1M | 5,618,728 |
| Pacer Advisors, Inc. | $91.2M | 2,359,239 |
| BRANDES INVESTMENT PARTNERS, LP | $82.1M | 4,430,642 |
| BlackRock, Inc. | $58.8M | 3,176,421 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $57.7M | 3,116,311 |
| RENAISSANCE TECHNOLOGIES LLC | $55.4M | 2,989,100 |
More Healthcare Companies
View all Healthcare →Put TAK on your watchlist
Track score changes the day TAKEDA PHARMACEUTICAL CO LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TAK a good stock to buy?
13F Pro's AI-powered analysis of TAKEDA PHARMACEUTICAL CO LTD (TAK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TAK are available on the TAK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TAK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TAK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TAKEDA PHARMACEUTICAL CO LTD's investment landscape.